Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus GIMOTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus GIMOTI.
CLOPRA-"YELLOW" vs GIMOTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
GIMOTI (metoclopramide) is a dopamine D2 receptor antagonist and also sensitizes tissues to acetylcholine, enhancing gastric motility and accelerating gastric emptying.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
10 mg orally three times daily.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life of 4-6 hours; prolonged in renal impairment (up to 10-14 hours).
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Primarily renal (60-70% unchanged); biliary/fecal 20-30% as metabolites.
Category C
Category C
Antiemetic/Prokinetic Agent
Prokinetic Agent